PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) from YaoPharma, a subsidiary of China’s leading drugmaker, Shanghai Fosun Pharmaceutical. YP05002 is currently being evaluated in phase I for treating obesity. Once-daily oral small molecule GLP-1 RAs are believed to have the […]

New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. A study led by researchers at Karolinska Institutet and Stockholm University […]

GLP‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations

Abstract Aim To pool the incremental net benefits (INBs) of using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treating obesity without diabetes. Materials and Methods PubMed, Embase, EconLit, CEA Registry, ProQuest Dissertation and Theses Global were searched from inception to April 2024. Cost-effectiveness studies were included if they reported economic outcomes of any GLP-1RAs in the […]

JCM, Vol. 14, Pages 8734: The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis

JCM, Vol. 14, Pages 8734: The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis Journal of Clinical Medicine doi: 10.3390/jcm14248734 Authors: Omar Abusedera Jana Sherif Malak Smida Salim Fredericks Background/Objectives: Type 2 diabetes mellitus (T2DM) is characterized by progressive β-cell dysfunction and insulin resistance. Glucagon-like […]

Is Tirzepatide Easier on the Eyes Than GLP-1s?

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients with type 2 diabetes than using GLP-1 receptor agonists, a study finds. Medscape Medical News